Please assess the completion status of the following clinical trial:

Trial Title: Study to Demonstrate the Non-inferiority of Olmesartan Medoxomil Versus Candesartan Cilexetil in Reducing Blood B-type (or Brain) Natriuretic Peptide Levels at Week 24

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, adult, out-patients aged between 18 and 85 years~* Patients with documented hospital admission within the previous 3 months before randomization with discharge diagnosis of CHF~* Patients with functional NYHA class II-IV with LVEF \< 40% assessed within the last 3 months~* Patients with blood BNP levels \> 400 pg/ml or NT-ProBNP levels \> 1500 pg/ml~* Patients with CHF due to ischemic heart disease, idiopathic dilated cardiomyopathy (IDC), mitral or aortic insufficiency or hypertension~* Patients with stable conventional treatment with diuretics, ACEI and/or beta-blockers and/or aldosterone antagonists for at least 2 months prior to randomisation, unless documented contraindication or intolerance~Exclusion Criteria:~* Females who are pregnant or plan a pregnancy during the time of the trial, are nursing or are of childbearing potential and not using acceptable methods of contraception. If a female becomes pregnant during the study, she has to be withdrawn immediately~* Patients with current hospitalisation due to heart failure~* Patients with stroke or transient ischemic attack (TIA) within the last 3 months~* Patients with acute coronary syndrome, myocardial infarction, coronary artery bypass or angioplasty within 3 months~* Planned cardiac surgery, revascularization or resynchronization within the study period~* Patients with operable valvular disease or significant obstructive cardiomyopathy~* Patients with bradycardia \[heart rate (HR) \< 50 bpm\]~* Patients with hypotension \[systolic blood pressure (SBP) \< 90 mmHg\]~* Patients with obstructive pneumopathy~* Patients with clinical significant renal failure (creatininemia \> 200 micromol/l)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).